Cagrilintide.
Long-acting amylin analogue — satiety regulation, often stacked with GLP-1.
Pre-compounded multi-peptide vials. An EU-licensed physician reviews the blend and dosing — anything they decline is refunded.
Build your bag, then either book a consultation (an EU-licensed physician reviews your file — anything declined is refunded) or upload an existing Rx at checkout.
- ✓Magistral preparation — Directive 2001/83/EC Art. 5(1).
- ✓Patient-named prescription only — dispensed against a valid Rx.
- ✓EU-GMP Annex 1 Grade A/B cleanroom compounding.
- ✓Cold-chain shipping across EU/EEA — 2–5 working days.
About Cagrilintide.
Cagrilintide is a long-acting analogue of amylin, a pancreatic hormone co-secreted with insulin that signals satiety. Its profile makes it complementary to GLP-1 agonists — the combination (e.g. CagriSema, Cagrilintide + Semaglutide) is in Phase 3 for obesity with promising early data.
Cagrilintide is mostly studied as part of a stacked protocol rather than as a stand-alone weight intervention.
Cagrilintide activates amylin receptors (AMY1, AMY2, AMY3) in the area postrema and other CNS sites. Activation slows gastric emptying, reduces glucagon secretion and produces a satiety signal independent of GLP-1.
Subcutaneous injection, once weekly. Typical doses range from 0.6 to 2.4 mg. Frequently administered together with Semaglutide on the same day.
Your physician sets the prescription. This is descriptive information, not a self-administration guide.
Lyophilised: store at 2–8 °C, protect from light. Once reconstituted: 2–8 °C, use within 30 days. Do not freeze.
- INN / Name
- Cagrilintide
- Form
- Lyophilised vial · subcutaneous injection
- Strength
- 5mg vial
- Manufacturing
- EU-GMP Annex 1 · Grade A/B
- Endotoxins
- European Pharmacopoeia 2.6.14 · LAL assay
- Identity & purity
- HPLC + MS · > 98%
- Cold chain
- Validated 2–8 °C, monitored end-to-end
- Regulatory basis
- Directive 2001/83/EC · Article 5(1)
2–5 working days
EU / EEA cold-chain delivery, 2–8 °C monitored end-to-end with digital temperature log. Tracking link sent on dispatch.
Magistral preparation
Patient-named preparation under Directive 2001/83/EC Article 5(1). Dispensed exclusively against a valid EU prescription.
EU prescription recognition
Prescriptions written in one EU member state are recognised in others under Directive 2011/24/EU on cross-border healthcare.
Within Weight Management.
- Cat. 06
Semaglutide
GLP-1 receptor agonist for appetite regulation and glycemic control.
€70.00 - Cat. 06
Tirzepatide
Dual GIP/GLP-1 agonist — broader metabolic effect than GLP-1 mono-agonists.
€120.00 - Cat. 06
Retatrutide
Triple GLP-1/GIP/glucagon agonist — under clinical investigation for advanced metabolic protocols.
€100.00